Holen Sie sich die Stockscreener-App
19.82
6.86%
-1.46
Handel nachbörslich:
19.82
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TNDM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$21.28
Offen:
$21.548
24-Stunden-Volumen:
1.59M
Relative Volume:
0.87
Marktkapitalisierung:
$1.32B
Einnahmen:
$796.00M
Nettoeinkommen (Verlust:
$-136.49M
KGV:
-9.4833
EPS:
-2.09
Netto-Cashflow:
$-64.24M
1W Leistung:
-4.34%
1M Leistung:
+18.19%
6M Leistung:
-35.29%
1J Leistung:
-62.90%
1-Tages-Spanne:
$19.71
$21.55
1-Wochen-Bereich:
$19.71
$21.98
52-Wochen-Spanne:
$15.75
$53.69
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Firmenname
Tandem Diabetes Care Inc
Sektor
Branche
Telefon
858-366-6900
Adresse
12400 HIGH BLUFF DRIVE, San Diego, CA
Vergleichen Sie TNDM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
19.82 | 1.38B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
133.58 | 228.44B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
105.26 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.64 | 143.93B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
82.98 | 103.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.22 | 43.99B | 5.54B | 4.18B | 623.10M | 7.00 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Mizuho | Neutral |
| 2025-03-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-10-04 | Eingeleitet | Goldman | Neutral |
| 2024-10-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Hochstufung | Stifel | Hold → Buy |
| 2023-08-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-15 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-08-09 | Herabstufung | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Underweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Eingeleitet | Wells Fargo | Overweight |
| 2020-07-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-18 | Bestätigt | Raymond James | Outperform |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-06 | Eingeleitet | Raymond James | Outperform |
| 2020-02-04 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Eingeleitet | Guggenheim | Buy |
| 2019-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2019-05-17 | Bestätigt | BofA/Merrill | Neutral |
| 2019-05-13 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-03-05 | Bestätigt | BofA/Merrill | Neutral |
| 2019-02-27 | Bestätigt | Lake Street | Buy |
| 2018-11-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-09-26 | Bestätigt | Piper Jaffray | Overweight |
Alle ansehen
Tandem Diabetes Care Inc Aktie (TNDM) Neueste Nachrichten
Tandem Diabetes Care Inc (TNDM) Shares Gap Down to $20.62 on May 30 - GuruFocus
Tandem Diabetes Care (TNDM) Up 6.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Contrasting Tandem Diabetes Care (NASDAQ:TNDM) and PolyPid (NASDAQ:PYPD) - Defense World
Cetera Investment Advisers Acquires 981 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Reflecting On Healthcare Technology Stocks’ Q1 Earnings: Tandem Diabetes (NASDAQ:TNDM) - Yahoo Finance
Tandem Diabetes and Roche Reach a Patent Settlement - MSN
Tandem Diabetes Care’s SWOT analysis: stock faces growth hurdles amid market shifts - Investing.com Nigeria
How the (TNDM) price action is used to our Advantage - news.stocktradersdaily.com
Tandem to pay Roche $36M in patent dispute settlement - MSN
Tandem Diabetes, Roche enter patent settlement agreement - Yahoo Finance
Tandem Diabetes Care (TNDM) Settles Patent Dispute with Roche - GuruFocus
Should Tandem Diabetes Stock Stay in Your Portfolio Now? - MSN
Tandem Diabetes To Pay Roche $36 Mln To Settle Patent Infringement Claim - Nasdaq
Tandem Diabetes Agrees to Pay Roche $36 Million in Patent Infringement Deal - marketscreener.com
Tandem Diabetes Care Settles Patent Disputes with Roche - TipRanks
Tandem Diabetes Care IncEnters Settlement Agreement With Roche EntitiesSEC Filing - marketscreener.com
Infusion Pumps Market to Hit USD 15.6 Billion by 2031, Driven - openPR.com
Deutsche Bank AG Purchases 19,308 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Bank of America Corp DE Sells 127,904 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Tandem Diabetes (TNDM) Price Target Raised by Citi, Neutral Rati - GuruFocus
Where Tandem Diabetes Care Stands With Analysts - Benzinga
Citigroup Maintains Neutral Rating on Tandem Diabetes Care (TNDM) | TNDM Stock News - GuruFocus
Tandem Diabetes Care Inc (TNDM) Trading Down 4.29% on May 21 - GuruFocus
Tandem Diabetes (TNDM) Price Target Raised by Citi, Neutral Rating Maintained | TNDM Stock News - GuruFocus
BNP Paribas Financial Markets Reduces Stock Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Global Insulin Pumps Market Report 2021-2030: Insulet, - openPR.com
Global Insulin Pumps Market Report 2021-2030: Insulet, Medtronic, and Tandem Diabetes Care are the Major Stakeholders – Focus Report Store - Barchart.com
Fortune Brands, Whirlpool, Align Technology, Tandem Diabetes, and STAAR Surgical Shares Plummet, What You Need To Know - Yahoo Finance
Tandem Diabetes Care Inc (TNDM) Trading 3.52% Higher on May 20 - GuruFocus
Tandem Diabetes at RBC Conference: Growth and Strategic Expansion By Investing.com - Investing.com Canada
Ameriprise Financial Inc. Sells 525,159 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Investor Network: Tandem Diabetes Care, Inc. to Host Earnings Call - ACCESS Newswire
Shareholders May Be More Conservative With Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) CEO Compensation For Now - simplywall.st
Insulin Pump Market Growth, Trends & Forecast 2025 | Leading key - openPR.com
TNDM Q1 Earnings Call: Product Expansion and Channel Initiatives Drive Growth Against Margin Pressures - Yahoo Finance
Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set - MassDevice
Tandem Diabetes Care gets FDA clearance for new set By Investing.com - Investing.com India
Tandem Diabetes Earnings: Despite Solid First-Quarter Results, We Expect Growth to Decelerate - Morningstar
Tandem Diabetes Care gets FDA clearance for new set - Investing.com
Tandem's Initial Growth Spurt From the Launch of Mobi Should Moderate in the Near Term - Morningstar
INVESTOR ALERT: Levi & Korsinsky Notifies Tandem Diabetes Care, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – TNDM - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Tandem Diabetes Care, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineTNDM - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Notifies Tandem Diabetes Care, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineTNDM - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Tandem Diabetes Care, Inc.(TNDM) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Reminds Tandem Diabetes Care, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2023TNDM - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Reminds Tandem Diabetes Care, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2023 – TNDM - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Tandem Diabetes Care, Inc. (TNDM) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Finanzdaten der Tandem Diabetes Care Inc-Aktie (TNDM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.36%
1.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):